1. (a) Deactivating, decontaminating, cleaning, disinfecting, and sporicidal agents shall be used in accordance with manufacturers' specifications, or subsequent manufacturer approved studies, and shall be surface compatible.
2. (b) Agents used for deactivation, decontamination, cleaning, and disinfecting all areas and equipment involved in the compounding of HDs or performing crushing or splitting tablets or opening capsules of antineoplastics HDs shall be applied through the use of wipes wetted with the appropriate solution.

In addition to the standards in USP Chapter 800, the following requirements apply to a facility where compounding HDs is performed or where crushing or splitting tablets or opening capsules of antineoplastic HDs is performed.

Note: Authority cited: Sections 4005, 4126.8 and 4127, Business and Professions Code. Reference: Sections 4005 and 4126.8, Business and Professions Code.

History

1. New section filed 6-19-2025; operative 10-1-2025 (Register 2025, No. 25).